Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering Plough’s Antipsychotic Saphris To Face FDA Panel Review In July

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Psychopharmacologic Drugs panel will likely consider supplemental data Schering submitted in response to an FDA complete response letter issued in January.

You may also be interested in...



Schering's Antipsychotic Saphris Should Have Easy Advisory Committee Review

Label for asenapine could be highly favorable on weight and adverse event issues given FDA's enthusiasm.

Schering's Antipsychotic Saphris Should Have Easy Advisory Committee Review

Label for asenapine could be highly favorable on weight and adverse event issues given FDA's enthusiasm.

Vanda’s Fanapt Approval Shows Evolution Of FDA’s Thinking

FDA's approval of Vanda's Fanapt (iloperidone) May 6 means that the bar for new atypical antipsychotic approvals may not be as high as it seemed 10 months ago, when FDA's "not approvable" letter on iloperidone requested an additional comparative trial

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel